PMID- 22937227
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120831
LR  - 20240418
IS  - 2090-1348 (Print)
IS  - 2090-1356 (Electronic)
IS  - 2090-1348 (Linking)
VI  - 2010
DP  - 2010
TI  - Evolution and prospects for intracranial pharmacotherapy for refractory 
      epilepsies: the subdural hybrid neuroprosthesis.
PG  - 725696
LID - 10.1155/2010/725696 [doi]
LID - 725696
AB  - Intracranial pharmacotherapy is a novel strategy to treat drug refractory, 
      localization-related epilepsies not amenable to resective surgery. The common 
      feature of the method is the use of some type of antiepileptic drug (AED) 
      delivery device placed inside the cranium to prevent or stop focal seizures. This 
      distinguishes it from other nonconventional methods, such as intrathecal 
      pharmacotherapy, electrical neurostimulation, gene therapy, cell transplantation, 
      and local cooling. AED-delivery systems comprise drug releasing polymers and 
      neuroprosthetic devices that can deliver AEDs into the brain via 
      intraparenchymal, ventricular, or transmeningeal routes. One such device is the 
      subdural Hybrid Neuroprosthesis (HNP), designed to deliver AEDs, such as 
      muscimol, into the subdural/subarachnoid space overlaying neocortical 
      epileptogenic zones, with electrophysiological feedback from the treated tissue. 
      The idea of intracranial pharmacotherapy and HNP treatment for epilepsy 
      originated from multiple sources, including the advent of implanted medical 
      devices, safety data for intracranial electrodes and catheters, evidence for the 
      seizure-controlling efficacy of intracerebral AEDs, and further understanding of 
      the pathophysiology of focal epilepsy. Successful introduction of intracranial 
      pharmacotherapy into clinical practice depends on how the intertwined scientific, 
      engineering, clinical, neurosurgical and regulatory challenges will be met to 
      produce an effective and commercially viable device.
FAU - Ludvig, Nandor
AU  - Ludvig N
AD  - Comprehensive Epilepsy Center, New York University School of Medicine, NYU 
      Langone Medical Center, 223 East 34th Street, New York, NY 10016, USA.
FAU - Medveczky, Geza
AU  - Medveczky G
FAU - French, Jacqueline A
AU  - French JA
FAU - Carlson, Chad
AU  - Carlson C
FAU - Devinsky, Orrin
AU  - Devinsky O
FAU - Kuzniecky, Ruben I
AU  - Kuzniecky RI
LA  - eng
PT  - Journal Article
DEP - 20100208
PL  - United States
TA  - Epilepsy Res Treat
JT  - Epilepsy research and treatment
JID - 101576602
PMC - PMC3428620
EDAT- 2010/01/01 00:00
MHDA- 2010/01/01 00:01
PMCR- 2010/02/08
CRDT- 2012/09/01 06:00
PHST- 2009/09/11 00:00 [received]
PHST- 2009/11/05 00:00 [accepted]
PHST- 2012/09/01 06:00 [entrez]
PHST- 2010/01/01 00:00 [pubmed]
PHST- 2010/01/01 00:01 [medline]
PHST- 2010/02/08 00:00 [pmc-release]
AID - 10.1155/2010/725696 [doi]
PST - ppublish
SO  - Epilepsy Res Treat. 2010;2010:725696. doi: 10.1155/2010/725696. Epub 2010 Feb 8.